Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.

doi:10.1007/s10549-016-3792-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.

Breast cancer research and treatment - 1 Apr 2016

González-Rivera Milagros, Lobo Miriam, López-Tarruella Sara, Jerez Yolanda, Del Monte-Millán María, Massarrah Tatiana, Ramos-Medina Rocío, Ocaña Inmaculada, Picornell Antoni, Santillán Garzón Sonia, Pérez-Carbornero Lucía, García-Saenz José A, Gómez Henry, Moreno Fernando, Márquez-Rodas Iván, Fuentes Hugo, Martin Miguel

Abstract excerpt

We describe the status and frequency of germline DNA genetic findings in an unselected prospective cohort of triple negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Study population includes 124 consecutive patients with stage II-III TNBC from a trial exploring the antitumor activity of neoadjuvant carboplatin/docetaxel chemotherapy enrolled between 2012 and March...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Carboplatin

Share to Clinical Trials as Topic

Share to Docetaxel

Share to Neoadjuvant Therapy

Share to Taxoids

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed

Identifiers

PMID: 27083178
DOI: 10.1007/s10549-016-3792-1

Genes

BRCA1
BARD1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.PMID 27083178Read ↗

Germline Mutations Related to Complete Remission after Neoadjuvant Chemotherapy in Patients with Triple-negative Breast CancerSemantic proximity Read ↗

Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.Semantic proximity Read ↗

Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.Semantic proximity Read ↗

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast CancerSemantic proximity Read ↗

Assessing germline mutational profile and its clinicopathological associations in Triple Negative Breast CancerSemantic proximity Read ↗

Germline Mutations in Triple-Negative Breast CancerSemantic proximity Read ↗

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.Semantic proximity Read ↗

The Impact of Germline BRCA Mutations in Locally Advanced, Triple Negative Breast Cancer Treated with Platinum Based Neoadjuvant ChemotherapySemantic proximity Read ↗

[Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].Semantic proximity Read ↗

Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.Semantic proximity Read ↗

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patientsSemantic proximity Read ↗

Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.